The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
|Videos|May 8, 2023
Interview with Bormioli Pharma’s Andrea Lodetti at DCAT
Author(s)Bormioli Pharma
Key Learning Objectives
- Italy’s Bormioli Pharma grew North American sales of its leading glass and plastic packaging for injectable drugs by 40% in 2022 while mobilizing a multimillion dollar investment program to expand its parental drug packaging solutions
- Celebrating its 200th anniversary, the company is pursuing ambitious “50-in-5” sustainability goals and commitments to alleviate industry supply chain shortages
- Bormioli Pharma supplies customers with complete packaging solutions, including innovative glass and plastic bottles; plastic, rubber and aluminum closures; and accessories
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains
3
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
4
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
5